image

The best stocks to buy since 1993

Our latest issue will be released in 8 days, don't miss out!

MPAC

February 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • MPAC
  • Price:
  • 550p
MPAC’s trading update said H2 was strong and it expects to report a pretax profit at £10.5m, implying 48% year-on-year growth. Net debt at the end of December was £37m although there are also £8m in invoiced receivables due in January. Having bought BCA and CSi in September and December,  the order book at the FY24 year-end grew significantly to £111m across healthcare and food & beverage verticals and provides coverage of >50% of this year’s forecast sales of £218m. Forecast EBIT is £19.5m (+68%) with a margin of 9% (-50bps YoY, reflecting the initial product mix post-acquisition) with pretax profit of £17.8m and EPS of 44.2p (+24%). Results are scheduled for release during the week beginning 28 April when it will flesh ou ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe